Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Heart failure fluid battle: which pill works better?

NCT ID NCT07199088

Disease control Sponsor: University of Health Sciences Lahore Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests two water pills—acetazolamide and metolazone—added to standard diuretics in 320 adults hospitalized with acute decompensated heart failure. The goal is to see which drug clears fluid buildup faster and more safely, reducing hospital stays and complications. Participants receive one of the two pills daily, and doctors track decongestion, kidney function, and side effects.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
acetazolamide and metolazone (diuretic drugs)
What this could lead to
If it works, this could identify a better add-on diuretic to help heart failure patients get rid of excess fluid faster and shorten hospital stays.
What could go wrong
This is a single-center study in Pakistan, so results may not apply to other populations. Both drugs can cause kidney problems or electrolyte imbalances, and the trial is not blinded, which could bias results.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 320 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Oct 2025

An estimate. Start dates often move.

Expected to finish

Oct 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Aged 18 years or older. * Diagnosed with Acute Decompensated Heart Failure (ADHF), with either preserved or reduced ejection fraction (EF). * At least one clinical sign of volume overload, such as: * Pleural effusion (confirmed by chest X-ray or ultrasound). * Oedema or ascites (verified by abdominal ultrasonography). * Plasma NT-proBNP level \> 1000 pg/mL or BNP level \> 250 ng/mL at screening. * Receiving at least 40 mg of furosemide as oral maintenance therapy for at least one month prior to the study initiation. Exclusion Criteria: * Previous use of acetazolamide or metolazone prior to the study period. * Known hypersensitivity or allergies to the study drugs (acetazolamide or metolazone) or their components. * Patients with electrolyte disturbances, especially hypokalemia. * End-stage renal disease requiring dialysis or GFR \< 20 mL/min/1.73 m². * Pregnant or breastfeeding women. * Severe hypotension (systolic blood pressure \< 90 mmHg) or other significant comorbidities like congenital cardiac illness requiring surgery. * Patients requiring renal replacement therapy during the hospitalization. * History of significant electrolyte imbalances or acid-base disturbances.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Acute decompensated heart failure are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

congestive heart failure diastolic heart failure heart failure systolic heart failure

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Acute decompensated heart failure Heart failure, diastolic Heart failure, systolic

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Quaid e Azam Medical College , bahawalpur

    RECRUITING

    Chak Four Hundred Fifty-four, Punjab Province, Pakistan

More trials for these conditions

Other studies related to the condition(s) this trial covers.